Press room
Newsletter
Theranostics Horizons Fall Edition 2009
Articles
Diagnostic Tools for Testicular Tumors ADVANCE, July 2009: Vol. 18 No. 7
Genetic Tests May Reveal Source of Mystery Tumors New York Times, March 2009
Press releases
| March 4, 2010 |
|
bioTheranostics Announces Commercial Availability of Expanded Tumor-Type Database for CancerTYPE ID® and the Launch of KRAS Testing |
| January 11, 2010 |
|
bioTheranostics Announces Commercial Agreement with Ferrer inCode to Market THEROS CancerTYPE ID® Molecular Cancer Classifier in Spain, Portugal, Greece, and Venezuela |
| December 12, 2009 |
|
Data from Three Clinical Studies of bioTheranostics’ Breast Cancer Molecular Test Presented at CTRC-AACR San Antonio Breast Cancer Symposium |
| November 17, 2009 |
|
bioMérieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment |
| October 6, 2009 |
|
bioTheranostics Announces Commercial Agreement with Lab21 |
| June 1, 2009 |
|
Data from Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting |
| May 6, 2009 |
|
Oncology Social Workers Report “Uncertain” and “Unknown” Cancers Significantly Increase Patient Distress |
| December 14, 2008 |
|
Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium |
| May 13, 2008 |
|
bioTheranostics Confirms that Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients |
| March 3, 2007 |
|
Center for Molecular Medicine Partners with bioTheranostics to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment |
| November 29, 2007 |
|
Study Links HOXB13 & IL17BR with Estrogen Signaling in Breast Cancer |
| October 5, 2007 |
|
bioTheranostics Presents at 2007 BIOCOM Investor Conference |
| October 2007 |
|
CONNECT Announces Finalists for 20th Annual Most Innovative New Product Awards |
| October 1, 2007 |
|
bioTheranostics Announces CAP Accreditation of Its Laboratory Operations |
| May 3, 2007 |
|
Researchers from Sweden Demonstrate H/I Can Predict the Benefit of Endocrine Therapy in Breast Cancer Patients |
| February 26, 2007 |
|
Researchers from Erasmus Cancer Center Validate the Clinical and Prognostic Utility of the HOXB13/IL17BR Ratio in Breast Cancer Patients |
For information about bioTheranostics or to speak with a company representative, please contact:
Wendy Johnson
bioTheranostics
(858) 587-5887 office
(760) 805-3905 cell
wendy.johnson@biotheranostics.com
Reporters on deadline who need immediate assistance may also contact:
Michele Parisi
(925) 429-1850 office
(925) 864-5028 cell
mparisi@biocommnetwork.com
